Reported about 23 hours ago
Morgan Stanley has initiated coverage of Cidara Therapeutics, Inc. (NASDAQ:CDTX) with a Buy rating and a price target of $190, mainly due to its lead antiviral candidate, CD388, which is expected to play a significant role in the influenza prevention market. Analyst Maxwell Skor highlighted the potential of CD388, noting its single-dose prevention capability and upcoming important phase 3 results anticipated in June 2026. The drug's Fast Track and Breakthrough Therapy designations and a sizable addressable market further support the investment outlook.
Source: YAHOO